1487461-37-9

Upstream product

• 3637-58-9 (cyclohexylmethyl)hydrazine dihydrochloride 
• 40876-98-0 sodium 1,4-diethoxy-1,4-dioxobut-2-en-2-olate 
• 3637-58-9 (cyclohexylmethyl)hydrazine hydrochloride 
• 762-21-0 acetylenedicarboxylic acid diethyl ester 

Downstream Products

• 1561965-55-6 ethyl 5-(3-(tert-butyl)-5-(1-methylcyclopropyl)phenyl)-1-(cyclohexylmethyl)-1H-pyrazole-3-carboxylate 
• 1561965-57-8 5-(3-(tert-butyl)-5-(1-methylcyclopropyl)phenyl)-1-(cyclohexylmethyl)-1H-pyrazole-3-carboxylic acid 
• 1561965-52-3 ethyl 1-(cyclohexylmethyl)-5-(((trifluoromethyl)sulfonyl)oxy)-1H-pyrazole-3-carboxylate 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE

The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.